Filter by:
Muscular Dystrophy
October 2024
World Muscle Society 2024
Sevasemten, a Fast Myosin Inhibitor, in Adults with Becker Muscular Dystrophy Results in Reduced Muscle Damage Biomarkers and Functional Stabilization
Muscular Dystrophy
October 2024
World Muscle Society 2024
Comparison of short- and long-term proteomic response to the fast skeletal myosin inhibitor, sevasemten (EDG-5506), in Becker muscular dystrophy (BMD)
Muscular Dystrophy
October 2024
World Muscle Society 2024
Exploring the Content Validity of Patient-Reported Outcome (PRO) Measures to Capture the Patient Experience of Becker Muscular Dystrophy (BMD)
Muscular Dystrophy
October 2024
World Muscle Society 2024
Rasch Evaluation of North Star Ambulatory Assessment and North Star Assessment for Limb-Girdle Type Muscular Dystrophies in Becker Muscular Dystrophy
Muscular Dystrophy
October 2024
World Muscle Society 2024
Understanding disease progression of Becker muscular dystrophy and a potential novel agent to protect muscle
Cardiovascular
September 2024
HFSA Annual Scientific Meeting 2024
CIRRUS-HCM: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of EDG-7500 in Adults with Hypertrophic Cardiomyopathy
Cardiovascular
September 2024
HFSA Annual Scientific Meeting 2024
EDG-7500, a First-in-Class Cardiac Sarcomere Modulator, Demonstrates Favorable Tolerability, Safety, and Pharmacokinetics in Healthy Adults
Cardiovascular
September 2024
HFSA Annual Scientific Meeting
CIRRUS-HCM: An Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of EDG-7500 in Adults with Hypertrophic Cardiomyopathy
Cardiovascular
July 2024
AHA Basic Cardiovascular Sciences meeting
